340 related articles for article (PubMed ID: 31332522)
1. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study.
Dottermusch M; Krüger S; Behrens HM; Halske C; Röcken C
Virchows Arch; 2019 Nov; 475(5):563-571. PubMed ID: 31332522
[TBL] [Abstract][Full Text] [Related]
2. Members of the EpCAM signalling pathway are expressed in gastric cancer tissue and are correlated with patient prognosis.
Warneke VS; Behrens HM; Haag J; Krüger S; Simon E; Mathiak M; Ebert MP; Röcken C
Br J Cancer; 2013 Oct; 109(8):2217-27. PubMed ID: 24008668
[TBL] [Abstract][Full Text] [Related]
3. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.
Wang C; Wang Y; Chen J; Wang Y; Pang C; Liang C; Yuan L; Ma Y
BMC Gastroenterol; 2023 Aug; 23(1):283. PubMed ID: 37582713
[TBL] [Abstract][Full Text] [Related]
4. RhoA, Claudin 18, and c-MET in Gastric Cancer: Clinicopathological Characteristics and Prognostic Significance in Curative Resected Patients.
Pereira MA; Ramos MFKP; Dias AR; Cardili L; Ribeiro RRE; de Castria TB; Zilberstein B; Nahas SC; Ribeiro U; de Mello ES
Med Sci (Basel); 2021 Dec; 10(1):. PubMed ID: 35076580
[No Abstract] [Full Text] [Related]
5. Loss of Tight Junction Protein Claudin 18 Promotes Progressive Neoplasia Development in Mouse Stomach.
Hagen SJ; Ang LH; Zheng Y; Karahan SN; Wu J; Wang YE; Caron TJ; Gad AP; Muthupalani S; Fox JG
Gastroenterology; 2018 Dec; 155(6):1852-1867. PubMed ID: 30195448
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus-associated gastric carcinoma: a distinct carcinoma of gastric phenotype by claudin expression profiling.
Shinozaki A; Ushiku T; Morikawa T; Hino R; Sakatani T; Uozaki H; Fukayama M
J Histochem Cytochem; 2009 Aug; 57(8):775-85. PubMed ID: 19398608
[TBL] [Abstract][Full Text] [Related]
7. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma.
Wang X; Zhang CS; Dong XY; Hu Y; Duan BJ; Bai J; Wu YY; Fan L; Liao XH; Kang Y; Zhang P; Li MY; Xu J; Mao ZJ; Liu HT; Zhang XL; Tian LF; Li EX
World J Gastrointest Oncol; 2022 Jul; 14(7):1252-1264. PubMed ID: 36051096
[TBL] [Abstract][Full Text] [Related]
8. Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer.
Baek JH; Park DJ; Kim GY; Cheon J; Kang BW; Cha HJ; Kim JG
Anticancer Res; 2019 Dec; 39(12):6973-6979. PubMed ID: 31810969
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.
Rohde C; Yamaguchi R; Mukhina S; Sahin U; Itoh K; Türeci Ö
Jpn J Clin Oncol; 2019 Sep; 49(9):870-876. PubMed ID: 31087075
[TBL] [Abstract][Full Text] [Related]
10. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases.
Coati I; Lotz G; Fanelli GN; Brignola S; Lanza C; Cappellesso R; Pellino A; Pucciarelli S; Spolverato G; Guzzardo V; Munari G; Zaninotto G; Scarpa M; Mastracci L; Farinati F; Realdon S; Pilati P; Lonardi S; Valeri N; Rugge M; Kiss A; Loupakis F; Fassan M
Br J Cancer; 2019 Jul; 121(3):257-263. PubMed ID: 31235864
[TBL] [Abstract][Full Text] [Related]
11. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion.
Angerilli V; Ghelardi F; Nappo F; Grillo F; Parente P; Lonardi S; Luchini C; Pietrantonio F; Ugolini C; Vanoli A; Fassan M
Pathol Res Pract; 2024 Feb; 254():155145. PubMed ID: 38277741
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the expression and genetic alteration of CLDN18 in gastric cancer.
Li J; Zhang Y; Hu D; Gong T; Xu R; Gao J
Aging (Albany NY); 2020 Jul; 12(14):14271-14284. PubMed ID: 32668412
[TBL] [Abstract][Full Text] [Related]
13. Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer.
Tao D; Guan B; Li Z; Jiao M; Zhou C; Li H
Pathol Res Pract; 2023 Aug; 248():154699. PubMed ID: 37487317
[TBL] [Abstract][Full Text] [Related]
14. Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination.
Ogawa H; Abe H; Yagi K; Seto Y; Ushiku T
Gastric Cancer; 2024 Jul; 27(4):802-810. PubMed ID: 38724721
[TBL] [Abstract][Full Text] [Related]
15. miR-1303 targets claudin-18 gene to modulate proliferation and invasion of gastric cancer cells.
Zhang SJ; Feng JF; Wang L; Guo W; Du YW; Ming L; Zhao GQ
Dig Dis Sci; 2014 Aug; 59(8):1754-63. PubMed ID: 24647998
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype.
Sanada Y; Oue N; Mitani Y; Yoshida K; Nakayama H; Yasui W
J Pathol; 2006 Apr; 208(5):633-42. PubMed ID: 16435283
[TBL] [Abstract][Full Text] [Related]
17. Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer.
Jasani B; Taniere P; Schildhaus HU; Blighe K; Parry S; Wilkinson D; Atkey N; Clare-Antony S; McCabe C; Quinn C; ; Dodson A
Lab Invest; 2024 Jan; 104(1):100284. PubMed ID: 37949357
[TBL] [Abstract][Full Text] [Related]
18. Claudin-18 deficiency results in alveolar barrier dysfunction and impaired alveologenesis in mice.
LaFemina MJ; Sutherland KM; Bentley T; Gonzales LW; Allen L; Chapin CJ; Rokkam D; Sweerus KA; Dobbs LG; Ballard PL; Frank JA
Am J Respir Cell Mol Biol; 2014 Oct; 51(4):550-8. PubMed ID: 24787463
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer.
Kubota Y; Kawazoe A; Mishima S; Nakamura Y; Kotani D; Kuboki Y; Bando H; Kojima T; Doi T; Yoshino T; Kuwata T; Shitara K
ESMO Open; 2023 Feb; 8(1):100762. PubMed ID: 36610262
[TBL] [Abstract][Full Text] [Related]
20. Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas.
Pellino A; Brignola S; Riello E; Niero M; Murgioni S; Guido M; Nappo F; Businello G; Sbaraglia M; Bergamo F; Spolverato G; Pucciarelli S; Merigliano S; Pilati P; Cavallin F; Realdon S; Farinati F; Dei Tos AP; Zagonel V; Lonardi S; Loupakis F; Fassan M
J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]